Top > Laboratories > Internal Medicine > Respiratory Medicine

Internal MedicineRespiratory Medicine


Our research projects include clinical and basic research on various types of pulmonary diseases. The target diseases are lung cancer, interstitial pneumonia, pulmonary infections, asthma, chronic obstructive pulmonary disease (COPD), etc. The aim of our projects is to create new treatment strategies for patients with these pulmonary diseases to improve their outcomes. We are actively involved in next-generation therapies including gene therapies, molecular target therapies, and immunomodulatory treatment.

Research Projects

1. Oncology [Basic Science]...

PIs: T. Hase, MD. PhD.; I. Tanaka, MD. PhD.
Aim of my research is clarifying molecular pathogenesis of lung cancer and malignant pleural mesothelioma (MPM) and then translating such knowledge into the clinic by developing new early detection, chemoprevention, and therapeutic strategies. Main project I have been working on as a principal investigator is to identify therapeutic targets that substantially contribute to malignant phenotypes of lung cancer and MPM. So far, we have identified several such targets that include ZEB1, EpCAM, TIMELESS and BMAL1. Now, we are setting up genome-wide approaches to identify more vital targets for the two diseases.

2. Oncology [Clinical Study]

PI: M. Morise, MD, PhD.
Lung cancer is the leading cause of death worldwide and the number of patients with MPM has been increasing. In addition, elderly patients have been becoming major population of these malignancies, and the optimal treatment selection in those has not been fully established because of their heterogeneity in feasibility of systemic chemotherapy.
Our research is aimed to establish the algorithm of optimal treatment selection in elderly patients with thoracic malignancies. As of today, we performed the multicenter cohort study clarifying the non-fit population for platinum-based combination chemotherapy in elderly patients with advanced non-small cell lung cancer (presented in European Society for Medical Oncology, 2014). In the study, non-hematological toxicity such as chemotherapy induced nausea and vomiting (CINV) was the major reason of early treatment termination without progressive disease.
We are also investigating the new strategy to control CINV, which is an important issue especially in elderly patients with thoracic malignancy as mentioned above. We are now planning to conduct a prospective cohort study identifying unproven useful bio-markers for predicting the risk of CINV.

3. Microenvironment of Lung fibrosis and Lung Cancer

PI: K.Sakamoto MD PhD.
Heterogeneity of fibroblasts such as bone-marrow progenitors and endothelial-derived fibroblasts through endothelial-mesenchymal transition (Endo-MT) is shown in pulmonary fibrosis. Heterogeneity of fibroblast provides tissue micornvironment under which pulmonary fibrosis itself progresses. The patients with emphysema and pulmonary fibrosis often have lung cancer. Emphysema/fibrosis might provides tissue microenvironment, in which many signaling are active, and consequently affect development of lung cancer and its malignant phenotypes such as epithelial/endothelial-mesenchymal transition (EMT). Now I am projecting the research to establish new therapeutic strategy targeting for the shared mechanism in development of emphysema/fibrosis and cancer. We are searching the critical molecules to negatively regulate tissue microenvironment, consequently controlling not only chronic lung disease but also lung cancer.

4. Respiratory Tract Infections

PI: Y. Shindo, MD, PhD.
"Creation of the Optimal Treatment Strategy for Respiratory Tract Infections"
Pneumonia is a common disease and one of the lethal diseases. In order to achieve the appropriate initial treatment, appropriate assessment and classification of patients with pneumonia at diagnosis is essential.
Our group is currently taking a multidimensional approach to pneumonia, including clinical epidemiology, microbiological epidemiology, and basic research on infection immunity and immunotherapies. As one of the representative work, we performed a multicenter prospective study on adult patients with pneumonia in Japan (Shindo Y, et al. Am J Respir Crit Care Med 2013; 188: 985-995). This study identified six important risk factors for drug-resistant pathogens and proposed a new clinical predictive rule for initial antibiotic selection. Furthermore, we clarified the risk factors for mortality in pneumonia patients who received appropriate antibiotic treatment (Shindo Y, et al. Lancet Infect Dis 2015; 15: 1055-1065). This study elucidated patients who may need adjunctive therapy other than antibiotic treatment. Using pathogens identified from patients with pneumonia, molecular epidemiological research has been also performed with microbiologists (Ito R, et al. J Clin Microbiol 2015; 53:879-886). In addition, our member is working on basic research on immunotherapies and immunological mechanisms with US researchers, in connection with the findings of our clinical research (Shindo Y, et al. J Leukoc Biol 2016 (in press)). Our group is going to develop these multidimensional research to create the future treatment strategy for pneumonia and other respiratory tract infections.

5. Bronchoscopy and Intervention

PI: T. Ito, MD, PhD.
I am mainly engaged in clinical practice and clinical research of respiratory medicine. In particularly, I am concerned with bronchoscopy. We perform more than 300 cases of fiberoptic bronchoscopy every year. From January to December 2014, we performed 57 cases of EBUS-TBNA (Endobronchial Ultrasound-guided Transbronchial Needle Aspiration) for mediastinal lymphnodes and 140 cases of EBUS-GS (Endobronchial Ultrasonography with a Guide Sheath) for pulmonary lesions. We perform other procedures such as local anesthetic thoracoscopy or bronchial occlusion using EWS (Endoscopic Watanabe Spigot) in daily practice. As clinical research, we have investigated efficacy and safety of midazolam for sedation during bronchoscopy (Respir Investig. 2014), echoic features of lymph nodes with sarcoidosis determined by endobronchial ultrasound (Intern Med. 2013), safety and usefulness of EBUS-TBNA in older patients (Geriatr Gerontol Int. 2013), and so on. We are aiming to perform safer, more accurate and more painless bronchoscopic procedures through clinical practice and research.

Faculty Members

ISHII Makoto, MD, PhD. Professor Respiratory Medicine
MORISE Masahiro, MD, PhD. Lecturer Respiratory Medicine
SHINDO Yuichiro, MD, PhD. Lecturer Respiratory Medicine
HASE Tetsunari, MD, PhD. Lecturer of hospital Respiratory Medicine
SAKAMOTO Koji, MD, PhD. Lecturer of hospital Respiratory Medicine
TANAKA Ichidai, MD, PhD. Assistant Professor Respiratory Medicine
ANDO Akira, MD, PhD. Assistant Professor Respiratory Medicine
HORI Kazumi, MD. Assistant Professor of hospital Respiratory Medicine
ITO Takayasu, MD, PhD. Assistant Professor of hospital Respiratory Medicine
KOYAMA Junji, MD. Assistant Professor of hospital Respiratory Medicine
HAYAI Shunsaku, MD. Assistant Professor of hospital Respiratory Medicine and Emergency Medicine


  • 2022
    1. Gen S, Tanaka I, Morise M, Koyama J, Kodama Y, Matsui A, Miyazawa A, Hase T, Hibino Y, Yokoyama T, Kimura T, Yoshida N, Sato M & Hashimoto N. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. BMC Cancer. 2022;22(1):654.
    2. Sano M, Shindo Y, Takahashi K, Okumura J, Sakakibara T, Murakami Y, Iguchi M, Yagi T, Matsui S, Hasegawa Y. Risk factors for antibiotic resistance in hospital-acquired and ventilator-associated pneumonia. J Infect Chemother. 2022;28(6):745-752.
    3. Thabet N, Shindo Y, Okumura J, Sano M, Sakakibara T, Murakami Y, Kobayashi H, Saka H, Kondo M, and Hasegawa Y, on behalf of the Central Japan. Clinical characteristics and risk factors for mortality in patients with community-acquired staphylococcal pneumonia. Nagoya J Med Sci. 2022;84(2):247-259.
    4. Ito T, Makino Y, Mashimo S, Baba T, Otsuki R, Yasui H, Fukui Y, Odate M, Arai Y, Okachi S, Wakahara K, Hashimoto N. Epidermal growth factor receptor mutation-positive advanced lung adenocarcinoma presenting with acute respiratory failure diagnosed by thin bronchoscope through transnasal route under high-concentration oxygen mask. Respirol Case Rep. 2022;10(9):e01007.
    5. Ito T, Okachi S, Sato K, Yasui H, Fukatsu N, Ando M, Chen-Yoshikawa TF, Saka H. Prevention of droplet dispersal with 'e-mask': A new daily use endoscopic mask during bronchoscopy. Respirology. 2022;27(10):863-873.
    6. Murakami Y, Shindo Y, Sano M, Okumura J, Kobayashi H, Sakakibara T, Iguchi M, Takahashi K, Yagi T, Matsui S, Hasegawa Y. Effects of lymphocyte and neutrophil counts and their time courses on mortality in patients with postoperative pneumonia. Sci Rep. 2022;12(1):14564.
    7. Suzuki A, Sakamoto K, Nakahara Y, Enomoto A, Hino J, Ando A, Inoue M, Shiraki Y, Omote N, Kusaka M, Fukihara J, Hashimoto N. BMP3b Is a Novel Antifibrotic Molecule Regulated by Meflin in Lung Fibroblasts. Am J Respir Cell Mol Biol. 2022;67(4):446-458.
    8. Ito T, Matsumoto Y, Okachi S, Nishida K, Tanaka M, Imabayashi T, Tsuchida T, Hashimoto N. A Diagnostic Predictive Model of Bronchoscopy with Radial Endobronchial Ultrasound for Peripheral Pulmonary Lesions. Respiration. 2022;101(12):1148-1156.
    9. Ito T, Okachi S, Iwano S, Kinoshita F, Wakahara K, Hashimoto N, Chen-Yoshikawa TF. Diagnostic value and safety of endobronchial ultrasonography with a guide sheath transbronchial biopsy for diagnosing peripheral pulmonary lesions in patients with interstitial lung disease. J Thorac Dis. 2022;14(11):4361-4371.
    10. Kobayashi H, Shindo Y, Kobayashi D, Sakakibara T, Murakami Y, Yagi M, Matsuura A, Sato K, Matsui K, Emoto R, Yagi T, Saka H, Matsui S, Hasegawa Y; Central Japan Lung Study Group. Extended-spectrum antibiotics for community-acquired pneumonia with a low risk for drug-resistant pathogens. Int J Infect Dis. 2022;124:124-132.
    11. Muto R, Fukuta S, Watanabe T, Shindo Y, Kanemitsu Y, Kajikawa S, Yonezawa T, Inoue T, Ichihashi T, Shiratori Y, Maruyama S. Predicting oxygen requirements in patients with coronavirus disease 2019 using an artificial intelligence-clinician model based on local non-image data. Front Med (Lausanne). 2022;9:1042067.
    12. Uematsu S, Kitazono S, Tanaka H, Saito R, Kawashima Y, Ohyanagi F, Tozuka T, Ryosuke T, Sakatani T, Horiike A, Yoshizawa T, Saiki M, Tambo Y, Koyama J, Kanazu M, Kudo K, Tsuchiya-Kawano Y, Yanagitani N, Nishio M. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01). Thorac Cancer. 2023;14(2):168-176.
    13. Shindo Y, Dela Cruz CS, Witzenrath M. Identification of two specific transcriptomic clusters of COVID-19 acute respiratory distress syndrome patients with different immune profiles and different outcomes. Eur Respir J. 2023;61(1):2202008.
    14. Majima S, Wakahara K, Iwano S, Kinoshita F, Nakamura M, Hashimoto N, Fujishiro M, Hasegawa Y. Airway involvement in inflammatory bowel disease: Inflammatory bowel disease patients have bronchial wall thickening. Respir Investig. 2022; 60(5): 713-719.
    15. Iwama S, Kobayashi T, Yasuda Y, Okuji T, Ito M, Ando M, Zhou X, Yamagami A, Onoue T, Kawaguchi Y, Miyata T, Sugiyama M, Takagi H, Hagiwara D, Suga H, Banno R, Hase T, Morise M, Wakahara K, Yokota K, Kato M, Nishio N, Tanaka C, Miyata K, Ogura A, Ito T, Sawada T, Shimokata T, Niimi K, Ohka F, Ishigami M, Gotoh M, Hashimoto N, Saito R, Kiyoi H, Kajiyama H, Ando Y, Hibi H, Sone M, Akiyama M, Kodera Y, Arima H. Increase Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline. J. Clin. Endocrinol. Metab. 2022; 107(4): e1620-e1630.
  • 2021
    1. Nishine H, Hiramoto T, Handa H, Inoue T, Wakahara K, Saka H, Miyazawa T, Mineshita M. Assessment of extensive airway obstruction using point-by-point lateral pressure measurements during bronchoscopy. Respiration. 2021; 100 (7): 611-617.
    2. Nishio N, Hiramatsu M, Goto Y, Shindo Y, Yamamoto T, Jingushi N, Wakahara K, Sone M. Surgical strategy and optimal timing of tracheostomy in patients with COVID-19: Early experiences in Japan. Auris Nasus Larynx. 2021; 48 (3): 518-524.
    3. Yasui H, Takahashi K, Taki S, Shimizu M, Koike C, Umeda K, Rahman S, Akashi T, Nguyen VS, Nakagawa Y, Sato K. Near Infrared Photo-Antimicrobial Targeting Therapy for Candida albicans.
    4. Advanced Therapeutics. 2021;9(4):1019.
    5. Yasui H, Nishinaga Y, Taki S, Takahashi K, Isobe Y, Sato K. Near Infrared Photoimmunotherapy for Mouse Models of Pleural Dissemination. J Vis Exp. 2021 Feb 9;(168). doi: 10.3791/61593.
    6. Taki S, Matsuoka K, Nishinaga Y, Takahashi K, Yasui H, Koike C, Shimizu M, Sato M, Sato K. Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity. J Immunother Cancer. 2021 Oct;9(11):e003036. doi: 10.1136/jitc-2021-003036.
    7. Matsuoka K, Sato M, Sato K. Hurdles for the wide implementation of photoimmunotherapy. Immunotherapy. 2021 Dec;13(17):1427-1438. doi: 10.2217/imt-2021-0241.
    8. Takahashi K, Taki S, Yasui H, Nishinaga Y, Isobe Y, Matsui T, Shimizu M, Koike C, Sato K. HER2 targeting near-infrared photoimmunotherapy for a CDDP-resistant small-cell lung cancer. Cancer Med. 2021 Dec;10(24):8808-8819. doi: 10.1002/cam4.4381.
    9. Furukawa K, Sato K, Okachi S, Kawashima H, Fujishiro M. Surgical mask designed for endoscopic procedures to prevent the diffusion of droplets. Acta Gastroenterol Belg. 2021 Jul-Sep;84(3):517-519. doi: 10.51821/84.3.024.
    10. Metersky ML, Aliberti S, Feldman C, Luna CM, Shindo Y, Sotgiu G, Waterer G. Never Let a Good Crisis Go to Waste. Chest. 2021 Mar;159(3):917-919. doi: 10.1016/j.chest.2020.10.018.
    11. Teramachi R, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Yokoyama T, Furukawa T, Yagi M, Sakamoto K, Hashimoto N, Hasegawa Y. Impact of post-capillary pulmonary hypertension on mortality in interstitial lung disease. Respir Investig. 2021 May;59(3):342-349. doi: 10.1016/j.resinv.2020.12.010.
    12. Omote N, Sakamoto K, Li Q, Schupp JC, Adams T, Ahangari F, Chioccioli M, DeIuliis G, Hashimoto N, Hasegawa Y, Kaminski N. Long noncoding RNA TINCR is a novel regulator of human bronchial epithelial cell differentiation state. Physiol Rep. 2021 Feb;9(3):e14727. doi: 10.14814/phy2.14727.
    13. Sakamoto K, Furukawa T, Yamano Y, Kataoka K, Teramachi R, Walia A, Suzuki A, Inoue M, Nakahara Y, Ryu C, Hashimoto N, Kondoh Y. Serum mitochondrial DNA predicts the risk of acute exacerbation and progression of idiopathic pulmonary fibrosis. Eur Respir J. 2021 Jan 21;57(1):2001346. doi: 10.1183/13993003.01346-2020.
    14. Takeuchi S, Yanagitani N, Seto T, Hattori Y, Ohashi K, Morise M, Matsumoto S, Yoh K, Goto K, Nishio M, Takahara S, Kawakami T, Imai Y, Yoshimura K, Tanimoto A, Nishiyama A, Murayama T, Yano S. Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET). Transl Lung Cancer Res. 2021 Jan;10(1):314-325. doi: 10.21037/tlcr-20-549.
    15. Ito T, Matsumoto M, Kujime M, Kohnoh T, Fukushima A, Takagi T, Fukushima Y, Kasahara T. Efficacy of endobronchial ultrasound-guided transbronchial biopsy without guide sheath for small peripheral pulmonary lesions (≤15 mm): A retrospective cohort study. Clin Respir J. 2021 Jun;15(6):622-627. doi: 10.1111/crj.13324.
    16. Ito T, Okachi S, Ishikawa Y, Shimada S, Wakahara K, Hashimoto N. Unusual presentation of recurrent follicular lymphoma as diffuse granular shadow. Respirol Case Rep. 2021 Feb 22;9(3):e00710. doi: 10.1002/rcr2.710.
    17. Nishikimi M, Nishida K, Shindo Y, Shoaib M, Kasugai D, Yasuda Y, Higashi M, Numaguchi A, Yamamoto T, Matsui S, Matsuda N. Failure of non-invasive respiratory support after 6 hours from initiation is associated with ICU mortality. PLoS One. 2021 Apr 30;16(4):e0251030. doi: 10.1371/journal.pone.0251030.
    18. Ikeda S, Misumi T, Izumi S, Sakamoto K, Nishimura N, Ro S, Fukunaga K, Okamori S, Tachikawa N, Miyata N, Shinkai M, Shinoda M, Miyazaki Y, Iijima Y, Izumo T, Inomata M, Okamoto M, Yamaguchi T, Iwabuchi K, Masuda M, Takoi H, Oyamada Y, Fujitani S, Mineshita M, Ishii H, Nakagawa A, Yamaguchi N, Hibino M, Tsushima K, Nagai T, Ishikawa S, Ishikawa N, Kondoh Y, Yamazaki Y, Gocho K, Nishizawa T, Tsuzuku A, Yagi K, Shindo Y, Takeda Y, Yamanaka T, Ogura T. Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study. Sci Rep. 2021 May 21;11(1):10727. doi: 10.1038/s41598-021-90246-y.
    19. Kasugai D, Ozaki M, Nishida K, Hiraiwa H, Jingushi N, Numaguchi A, Omote N, Shindo Y, Goto Y. Usefulness of Respiratory Mechanics and Laboratory Parameter Trends as Markers of Early Treatment Success in Mechanically Ventilated Severe Coronavirus Disease: A Single-Center Pilot Study. J Clin Med. 2021 Jun 6;10(11):2513. doi: 10.3390/jcm10112513.
    20. Inoue M, Sakamoto K, Suzuki A, Nakai S, Ando A, Shiraki Y, Nakahara Y, Omura M, Enomoto A, Nakase I, Sawada M, Hashimoto N. Size and surface modification of silica nanoparticles affect the severity of lung toxicity by modulating endosomal ROS generation in macrophages. Part Fibre Toxicol. 2021 Jun 17;18(1):21. doi: 10.1186/s12989-021-00415-0.
    21. Nakahara Y, Hashimoto N, Sakamoto K, Enomoto A, Adams TS, Yokoi T, Omote N, Poli S, Ando A, Wakahara K, Suzuki A, Inoue M, Hara A, Mizutani Y, Imaizumi K, Kawabe T, Rosas IO, Takahashi M, Kaminski N, Hasegawa Y. Fibroblasts positive for meflin have anti-fibrotic properties in pulmonary fibrosis. Eur Respir J. 2021 Dec 23;58(6):2003397. doi: 10.1183/13993003.03397-2020.
    22. Suzuki A, Sakaguchi H, Sakamoto K, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Sugiyama Y, Kudoh S, Nukiwa T, Miyazawa S, Kondoh Y. The Effect of Pirfenidone on the Prescription of Antibiotics and Antitussive Drugs in Patients With Idiopathic Pulmonary Fibrosis: A Post Hoc Exploratory Analysis of Phase III Clinical Trial. Chest. 2021 Oct;160(4):1372-1376. doi: 10.1016/j.chest.2021.05.058.
    23. Yukawa H, Yamazaki S, Aoki K, Muto K, Kihara N, Sato K, Onoshima D, Ochiya T, Tanaka Y, Baba Y. Co-continuous structural effect of size-controlled macro-porous glass membrane on extracellular vesicle collection for the analysis of miRNA. Sci Rep. 2021 Apr 21;11(1):8672. doi: 10.1038/s41598-021-87986-2.
    24. Yasui H, Nishinaga Y, Taki S, Takahashi K, Isobe Y, Shimizu M, Koike C, Taki T, Sakamoto A, Katsumi K, Ishii K, Sato K. Near-infrared photoimmunotherapy targeting GPR87: Development of a humanised anti-GPR87 mAb and therapeutic efficacy on a lung cancer mouse model. EBioMedicine. 2021 May;67:103372. doi: 10.1016/j.ebiom.2021.103372.
    25. Nakagawa K, Kijima T, Okada M, Morise M, Kato M, Hirano K, Fujimoto N, Takenoyama M, Yokouchi H, Ohe Y, Hida T, Aoe K, Kishimoto T, Hirokawa M, Matsuki H, Kaneko Y, Yamada T, Morimoto C, Takeda M. Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma. JTO Clin Res Rep. 2021 Apr 29;2(6):100178. doi: 10.1016/j.jtocrr.2021.100178.
    26. Nakano T, Kuribayashi K, Kondo M, Morise M, Tada Y, Hirano K, Hayashi M, Tanaka M, Hirabayashi M. Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study. Asia Pac J Clin Oncol. 2021 Jun;17(3):264-272. doi: 10.1111/ajco.13455. Epub 2020 Sep 7.
    27. Hashimoto N, Wakahara K, Sakamoto K. The Importance of Appropriate Diagnosis in the Practical Management of Chronic Obstructive Pulmonary Disease. Diagnostics (Basel). 2021 Mar 30;11(4):618. doi: 10.3390/diagnostics11040618.
    28. Dela Cruz CS, Evans SE, Restrepo MI, Dean N, Torres A, Amara-Elori I, Awasthi S, Caler E, Cao B, Chalmers JD, Chastre J, Cohen TS, Cohen AH, Crothers K, Di YP, Egan ME, Feldman C, Gautam S, Halstead ES, Herold S, Jones BE, Luna C, Niederman MS, Mendez R, Menendez R, Mizgerd JP, Nusrat R, Ramirez J, Shindo Y, Waterer G, Yeligar SM, Wunderink RG. Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report. Ann Am Thorac Soc. 2021 Jul;18(7):1087-1097. doi: 10.1513/AnnalsATS.202102-209ST.
    29. Aronson KI, Danoff SK, Russell AM, Ryerson CJ, Suzuki A, Wijsenbeek MS, Bajwah S, Bianchi P, Corte TJ, Lee JS, Lindell KO, Maher TM, Martinez FJ, Meek PM, Raghu G, Rouland G, Rudell R, Safford MM, Sheth JS, Swigris JJ. Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2021 Jul 15;204(2):e3-e23. doi: 10.1164/rccm.202105-1193ST. Erratum in: Am J Respir Crit Care Med. 2021 Sep 1;204(5):616.
    30. Shibata H, Takeda N, Suzuki Y, Katoh T, Yoshida N, Hasegawa Y, Yamaguchi E, Hashimoto N, Ito S. <Editors' Choice> Effects of high-flow nasal cannula oxygen therapy on oral intake of do-not-intubate patients with respiratory diseases. Nagoya J Med Sci. 2021 Aug;83(3):509-522. doi: 10.18999/nagjms.83.3.509.
    31. Yasui H, Okachi S, Fukatsu N, Sato K. Development of a Mask for Bronchoscopy to Prevent Infection during the COVID-19 Pandemic: Image Evaluation. Am J Respir Crit Care Med. 2021 Sep 1;204(5):e56-e58. doi: 10.1164/rccm.202010-4037IM.
    32. Takahashi K, Okachi S, Yasui H, Taki S, Ito T, Fukatsu N, Sato K. New style for nasopharyngeal swab with a mask: image-evaluation. Int J Infect Dis. 2021 Aug;109:112-113. doi: 10.1016/j.ijid.2021.06.039.
    33. Shindo Y, Kondoh Y, Kada A, Doi Y, Tomii K, Mukae H, Murata N, Imai R, Okamoto M, Yamano Y, Miyazaki Y, Shinoda M, Aso H, Izumi S, Ishii H, Ito R, Saito AM, Saito TI, Hasegawa Y. Phase II Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure. Infect Dis Ther. 2021 Dec;10(4):2353-2369. doi: 10.1007/s40121-021-00512-9.
    34. Sakai H, Morise M, Kato T, Matsumoto S, Sakamoto T, Kumagai T, Tokito T, Atagi S, Kozuki T, Tanaka H, Chikamori K, Shinagawa N, Takeoka H, Bruns R, Straub J, Schumacher KM, Paik PK. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study. Jpn J Clin Oncol. 2021 Aug 1;51(8):1261-1268. doi: 10.1093/jjco/hyab072.
    35. Aronson KI, Suzuki A. Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World? Front Med (Lausanne). 2021 Oct 6;8:745908. doi: 10.3389/fmed.2021.745908.
    36. Kasugai D, Jingushi N, Omote N, Shindo Y, Goto Y. The Mystery of Futility of Appropriate Antibiotics for Coinfection in COVID-19. Am J Respir Crit Care Med. 2021 Dec 15;204(12):1489. doi: 10.1164/rccm.202107-1656LE.
    37. Ito T, Kimura T, Kataoka K, Okachi S, Wakahara K, Hashimoto N, Kondoh Y. A Pilot Study of Transbronchial Biopsy Using Endobronchial Ultrasonography with a Guide Sheath in the Diagnosis of Peripheral Pulmonary Lesions in Patients with Interstitial Lung Disease. Diagnostics (Basel). 2021 Dec 4;11(12):2269. doi: 10.3390/diagnostics11122269.
    38. Ito T, Okachi S, Kimura T, Kataoka K, Suzuki Y, Kinoshita F, Wakahara K, Hashimoto N, Kondoh Y. Endobronchial Ultrasonography with a Guide Sheath Transbronchial Biopsy for Diagnosing Peripheral Pulmonary Lesions within or near Fibrotic Lesions in Patients with Interstitial Lung Disease. Cancers (Basel). 2021 Nov 17;13(22):5751. doi: 10.3390/cancers13225751.
    39. Ito T, Okachi S, Ikenouchi T, Ushijima F, Ohashi T, Ogawa M, Nagahama M, Hashimoto N. The Value of Additional Conventional Transbronchial Biopsy in the Negative Results of Rapid On-site Evaluation During Endobronchial Ultrasound With Guide Sheath to Diagnose Small Peripheral Lung Cancer. Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211043040. doi: 10.1177/15330338211043040.
    40. Tanaka I, Morise M. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations. Int J Mol Sci. 2021 Dec 27;23(1):245. doi: 10.3390/ijms23010245.
    41. Yasuda H, Ichihara E, Sakakibara-Konishi J, Zenke Y, Takeuchi S, Morise M, Hotta K, Sato M, Matsumoto S, Tanimoto A, Matsuzawa R, Kiura K, Takashima Y, Yano S, Koyama J, Fukushima T, Hamamoto J, Terai H, Ikemura S, Takemura R, Goto K, Soejima K. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer. 2021 Dec;162:140-146. doi: 10.1016/j.lungcan.2021.10.006.
    42. Ozone S, Ichikawa K, Morise M, Matsui A, Kinoshita F, Matsuzawa R, Koyama J, Tanaka I, Hashimoto N. Is area under the curve the best parameter for carboplatin induced emetic risk stratification? Nagoya J Med Sci. 2021 Nov;83(4):773-785. doi: 10.18999/nagjms.83.4.773.
    43. Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC, Andric Z, Mocci S, Enquist I, Komatsubara K, McCleland M, Kuriki H, Villalobos M, Phan S, Spigel DR, Herbst RS. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. J Thorac Oncol. 2021 Nov;16(11):1872-1882. doi: 10.1016/j.jtho.2021.06.019.
    44. Ishi A, Tanaka I, Iwama S, Sakakibara T, Mastui T, Kobayashi T, Hase T, Morise M, Sato M, Arima H, Hashimoto N. Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series. Endocr J. 2021 May 28;68(5):613-620. doi: 10.1507/endocrj.EJ20-0769.
    45. Kodama Y, Tanaka I, Sato T, Hori K, Gen S, Morise M, Matsubara D, Sato M, Sekido Y, Hashimoto N. Oxytocin receptor is a promising therapeutic target of malignant mesothelioma. Cancer Sci. 2021 Sep;112(9):3520-3532. doi: 10.1111/cas.15025.
    46. Tanaka I, Furukawa T, Morise M. The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence. Cancer Cell Int. 2021 Aug 26;21(1):454. doi: 10.1186/s12935-021-02165-7.
  • 2020
    1. Isobe Y, Sato K, Nishinaga Y, Takahashi K, Taki S, Yasui H, Shimizu M, Endo R, Koike C, Kuramoto N, Yukawa H, Nakamura S, Fukui T, Kawaguchi K, Yoshikawa C. TF, Baba Y, Hasegawa Y. Near Infrared Photoimmunotherapy Targeting DLL3 For Small Cell Lung Cancer. EBioMedicine. 2020; 52: 102632.
    2. Tanaka I, Morise M, Miyazawa A, Kodama Y, Tamiya Y, Gen S, Matsui A, Hase T, Hashimoto N, Sato M, Hasegawa Y. Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation. Clin Lung Cancer 2020; 21: 273-280.e4. doi: 10.1016/j.cllc.2020.01.011
    3. Goto D, Komeda K, Uwatoko N, Nakashima M, Koike M, Kawai K, Kodama Y, Miyazawa A, Tanaka I, Hase T, Morise M, Hasegawa Y, Kawabe T, Sato M. UHRF1, a regulator of methylation, as a diagnostic and prognostic marker for lung cancer. Cancer Invest 2020; 38: 240-249. doi: 10.1080/07357907.2020.1747483
    4. Nakano A, Ohkubo H, Taniguchi H, Kondoh Y, Matsuda T, Yagi M, Furukawa T, Kanemitsu Y, Niimi A. Early decrease in erector spinae muscle area and future risk of mortality in idiopathic pulmonary fibrosis. Sci Rep 2020; 10: 2312. doi: 10.1038/s41598-020-59100-5
    5. Suzuki A, Ando M, Kimura T, Kataoka K, Yokoyama T, Shiroshita E, Kondoh Y. The impact of high-flow nasal cannula oxygen therapy on exercise capacity in fibrotic interstitial lung disease: a proof-of-concept randomized controlled crossover trial. BMC Pulm Med 2020; 20: 51. doi: 10.1186/s12890-020-1093-2
    6. Takei R, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, Kimura T, Furukawa T, Takahashi O, Chiba H, Takahashi H, Kondoh Y. Pulse oximetry saturation can predict prognosis of idiopathic pulmonary fibrosis. Respir investig 2020; 58: 190-195. doi: 10.1016/j.resinv.2019.12.010
    7. Ito T, Okachi S, Ikenouchi T, Ushijima F, Ohashi T, Ogawa M, Nagahama M, Wakahara K, Hashimoto N. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Under Non-Invasive Positive Pressure for the Diagnosis of Lung Metastasis Due to Renal Cell Carcinoma in a Patient With Respiratory Failure. Respir Med Case Rep 2020; 29: 101028. doi: 10.1016/j.rmcr.2020.101028
    8. Shimokawa M, Nosaki K, Seto T, Ohashi K, Morise M, Horinouchi H, Sakakibara J, Murakami H, Yano S, Satouchi M, Matsumoto S, Goto K, Yoh K. Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study. Trials 2020; 21: 298. doi: 10.1186/s13063-020-4221-7
    9. Nakagawa K, Hida T, Nokihara H, Morise M, Azuma K, Kim YH, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Koyama R, Mitsudomi T, Yamamoto N, Asakawa T, Hayashi M, Hasegawa W, Tamura T. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer 2020; 139: 195-199. doi: 10.1016/j.lungcan.2019.11.025
    10. Nishinaga Y, Sato K, Yasui H, Taki S, Takahashi K, Shimizu M, Endo R, Koike C, Kuramoto N, Nakamura S, Fukui T, Yukawa H, Baba Y, Kaneko K.M, Chen-Yoshikawa TF, Kobayashi H, Kato Y, Hasegawa Y. Targeted Phototherapy for Malignant Pleural Mesothelioma: Near Infrared Photoimmunotherapy Targeting Podoplanin. Cells 2020; 9: 1019. doi: 10.3390/cells9041019
    11. Hayashi H, Fukutomi Y, Mitsui C, Kajiwara K, Watai K, Kamide Y, Nakamura Y, Hamada Y, Tomita Y, Sekiya K, Tsuburai T, Izuhara K, Wakahara K, Hashimoto N, Hasegawa Y, Taniguchi M. Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease, A Randomized Trial. Am J Respir Crit Care Med 2020; 201: 1488-1498. doi: 10.1164/rccm.201906-1215OC
    12. Suzuki A, Kondoh Y, Brown KK, Johkoh T, Kataoka K, Fukuoka J, Kimura T, Matsuda T, Yokoyama T, Fukihara J, Ando M, Tanaka T, Hashimoto N, Sakamoto K, Hasegawa Y. Acute exacerbations of fibrotic interstitial lung diseases. Respirology 2020; 25: 525-534. doi: 10.1111/resp.13682
    13. Sato K. The “light” guide for surgery. EBioMedicine. 2020; 56: 102808. doi: 10.1016/j.ebiom.2020.102808
    14. Hiramatsu M, Nishio N, Ozaki M, Shindo Y, Suzuki K, Yamamoto T, Fujimoto Y, Sone M. Anesthetic and surgical management of tracheostomy in a patient with COVID-19. Auris Nasus Larynx 2020; 47: 472-476. doi: 10.1016/j.anl.2020.04.002
    15. Choi M, Hegerle N, Nkeze J, Sen S, Jamindar S, Nasrin S, Sen S, Permala-Booth J, Sinclair J, Tapia MD, Johnson JK, Mamadou S, Thaden JT, Fowler Jr. VG, Aguilar A, Terán E, Decre D, Morel F, Krogfelt KA, Brauner A, Protonotariou E, Christaki E, Shindo Y, Lin YT, Kwa AL, Shakoor S, Singh-Moodley A, Perovic O, Jacobs J, Lunguya O, Simon R, Cross A, Tennant SM. The Diversity of Lipopolysaccharide (O) and Capsular Polysaccharide (K) Antigens of Invasive Klebsiella pneumoniae in a Multi-Country Collection. Front Microbiol 2020; 11: 1249. doi: 10.3389/fmicb.2020.01249
    16. Fukihara J, Kondoh Y, Brown KK, Kimura T, Kataoka K, Matsuda T, Yamano Y, Suzuki A, Furukawa T, Sumikawa H, Takahashi O, Johkoh T, Tanaka T, Fukuoka J, Hashimoto N, Hasegawa Y. Probable usual interstitial pneumonia pattern on chest CT: is it sufficient for a diagnosis of idiopathic pulmonary fibrosis? Eur Respir J 2020; 55: 1802465. doi: 10.1183/13993003.02465-2018
    17. Nishio N, Hiramatsu M, Goto Y, Shindo Y, Yamamoto T, Jingushi N, Wakahara K, Sone M. Surgical strategy and optimal timing of tracheostomy in patients with COVID-19: Early experiences in Japan. Auris Nasus Larynx 2020; 45: 518-524. doi: 10.1016/j.anl.2020.11.004
    18. Matsui A, Morise M, Tanaka I, Ozone S, Matsuzawa R, Koyama J, Hase T, Hashimoto N, Sato M, Hasegawa Y. Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer. Cancer Invest 2020; 38: 424-430. doi: 10.1080/07357907.2020.1793350
    19. Seto T, Hayashi H, Satouchi M, Goto Y, Niho S, Nogami N, Hida T, Takahashi T, Sakakibara-Konishi J, Morise M, Nagasawa T, Suzuki M, Ohkura M, Fukuhara K, Thurm H, Peltz G, Nishio M. Lorlatinib in previously-treated ALK-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study. Cancer Sci 2020; 111: 3726-3738. doi: 10.1111/cas.14576
    20. Majima S, Wakahara K, Nishio T, Nishio N, Teranishi M, Iwano S, Hirakawa A, Hashimoto N, Sone M, Hasegawa Y. Bronchial wall thickening is associated with severity of chronic rhinosinusitis. Respir Med 2020; 170: 106024. doi: 10.1016/j.rmed.2020.106024
    21. Oi H, Suzuki A, Yamano Y, Yokoyama T, Matsuda T, Kataoka K, Suzuki Y, Kimura T, Kondoh Y. Mesalazine-induced lung injury with severe respiratory failure successfully treated with steroids and non-invasive positive pressure ventilation. Respir Med Case Rep 2020; 31: 101157. doi: 10.1016/j.rmcr.2020.101157
    22. Pletz M, Blasi F, Chalmers J, Dela Cruz C, Feldman C, Luna C, Ramirez J, Shindo Y, Stolz D, Torres A, Webb B, Welte T, Wunderink R, Aliberti S. International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline: A Critical Appraisal by a Global Expert Panel. Chest 2020; 158: 1912-1918. doi: 10.1016/j.chest.2020.07.089
    23. Sakamoto K, Fukihara J, Morise M, Hashimoto N. Clinical burden of immune checkpoint inhibitor-induced pneumonitis. Respir Investig 2020; 58: 305-319. 10.1016/j.resinv.2020.05.008
    24. Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y. Reply to \"Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death-1 Inhibitors\". Clin Lung Cancer 2020; 21: e205. doi: 10.1016/j.cllc.2019.11.013
    25. Omote N, Matsuda N, Hashimoto N, Nishida K, Sakamoto K, Ando A, Nakahara Y, Nishikimi M, Higashi M, Matsui S, Hasegawa Y. High-flow nasal cannula therapy for acute respiratory failure in patients with interstitial pneumonia: a retrospective observational study. Nagoya J Med Sci 2020; 82: 301-313. 10.18999/nagjms.82.2.301
    26. Asai F, Seki T, Sugawara-Narutaki A, Sato K, Odent J, Coulembier O, Raquez JM, Takeoka Y. Tough and Three-Dimensional-Printable Poly(2-methoxyethyl acrylate)-Silica Composite Elastomer with Antiplatelet Adhesion Property. ACS Appl Mater Interfaces. 2020; 12: 46621-46628. doi: 10.1021/acsami.0c11416
    27. Arizono S, Furukawa T, Taniguchi H, Sakamoto K, Kimura T, Kataoka K, Ogawa T, Watanabe F, Kondoh Y. Supplemental oxygen improves exercise capacity in IPF patients with exertional desaturation. Respirology 2020; 25: 1152-1159. doi: 10.1111/resp.13829
    28. Ramirez JA, Musher DM, Evans SE, Cruz CD, Crothers KA, Hage CA, Aliberti S, Anzueto A, Arancibia F, Arnold F, Azoulay E, Blasi F, Bordon J, Burdette S, Cao B, Cavallazzi R, Chalmers J, Charles P, Chastre J, Claessens YE, Dean N, Duval X, Fartoukh M, Feldman C, File T, Froes F, Furmanek S, Gnoni M, Lopardo G, Luna C, Maruyama T, Menendez R, Metersky M, Mildvan D, Mortensen E, Niederman MS, Pletz M, Rello J. Restrepo MI, Shindo Y, Torres A, Waterer G, Webb B, Welte T, Witzenrath M, Wunderink R. Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. Chest 2020; 158: 1896-1911. doi: 10.1016/j.chest.2020.05.598
    29. Murakami Y, Sakamoto K, Okumura Y, Suzuki A, Mii S, Sato M, Yokoi T, Hashimoto N, Hasegawa Y. Acute Exacerbation of Pleuroparenchymal Fibroelastosis Secondary to Allogenic Hematopoietic Stem Cell Transplantation. Intern Med 2020; 59: 2737-2743. doi: 10.2169/internalmedicine.4995-20
    30. Sugiyama T, Matsushima M, Ohdachi T, Hashimoto N, Hasegawa Y, Yokoi K, Kawabe T. Involvement of heme oxygenase-1 in suppression of T cell activation by quercetin. Immunopharmacol Immunotoxicol 2020; 42: 295-305.
    31. Kobayashi T, Iwama S, Yasuda Y, Okada N, Okuji T, Ito M, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Fujimoto Y, Hibi H, Sone M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study. J Immunother Cancer 2020; 8: e000779. doi: 10.1136/jitc-2020-000779
    32. Okada N, Iwama S, Okuji T, Kobayashi T, Yasuda Y, Wada E, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Hase T, Morise M, Kanda M, Yokota K, Hashimoto N, Ando M, Fujimoto Y, Nagino M, Kodera Y, Fujishiro M, Hibi H, Sone M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: A prospective study. Br J Cancer 2020; 122: 771-777. doi: 10.1038/s41416-020-0736-7
    33. Saito T, Kishi K, Tomii K, Sakamoto N, Aoshima M, Araya J, Izumi S, Arita M, Abe M, Yamauchi H, Shindoh J, Suda T, Okamoto M, Ebina M, Yamada Y, Tohda Y, Kawamura T, Taguchi Y, Ishii H, Hashimoto N, Abe S, Taniguchi H, Tagawa J, Bessho K, Yamamori N, Homma S. Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial. Am J Respir Crit Care Med 2020; 201: 1110-1119.
    34. Kondoh Y, Azuma A, Inoue Y, Ogura T, Sakamoto S, Tsushima K, Johkoh T, Fujimoto K, Ichikado K, Matsuzawa Y, Saito T, Kishi K, Tomii K, Sakamoto N, Aoshima M, Araya J, Izumi S, Arita M, Abe M, Yamauchi H, Shindoh J, Suda T, Okamoto M, Ebina M, Yamada Y, Tohda Y, Kawamura T, Taguchi Y, Ishii H, Hashimoto N, Abe S, Taniguchi H, Tagawa J, Bessho K, Yamamori N, Homma S. Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial. Am J Respir Crit Care Med 2020; 201: 1110-1119.
    35. Suzuki M, Cao K, Kato S, Mizutani N, Tanaka K, Arima C, Tai MC, Nakatani N, Yanagisawa K, Takeuchi T, Shi H, Mizutani Y, Niimi A, Taniguchi T, Fukui T, Yokoi K, Wakahara K, Hasegawa Y, Mizutani Y, Iwaki S, Fujii S, Sato A, Tamiya-Koizumi K, Murate T, Kyogashima M, Tomida S. CERS6 required for cell migration and metastasis in lung cancer. J Cell Mol Med 2020; 24: 11949-11959. doi: 10.1111/jcmm.15817
    36. Mizuno K, Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Kawashima H, Inukai Y, Toyoda H, Yokota K, Hase T, Maeda O, Kiyoi H, Nagino M, Hibi H, Kodera Y, Fujimoto Y, Sone M, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Fujishiro M. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol 2020; 55: 653-661. doi: 10.1007/s00535-020-01677-9
    37. Urakawa H, Ando Y, Hase T, Kikumori T, Arai E, Maeda O, Mitsuma A, Sugishita M, Shimokata T, Ikuta K, Ishiguro N, Nishida Y. Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: a prospective cohort study. Int J Cancer 2020; 146: 3504-3515. doi: 10.1002/ijc.32836
    38. Takeuchi S, Hase T, Shimizu S, Ando M, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Katakami N, Takahashi T, Hasegawa Y, Ko TK, Ong ST, Yano S. Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double‐positive lung cancer. Cancer Sci 2020; 111: 561-570. PMID: 31782583
    39. Ninomiya K, Teraoka S, Zenke Y, Kenmotsu H, Nakamura Y, Okuma Y, Tamiya A, Nosaki K, Morise M, Aokage K, Oya Y, Kozuki T, Sakamoto T, Tanaka K, Tanaka H, Tanizaki J, Miura S, Mizutani H, Miyauchi E, Yamaguchi O, Ebi N, Goto Y, Sasaki T, Daga H, Morita S, Yamanaka T, Amano S, Hasegawa K, Imamura CK, Suzuki K, Nakajima K, Nishimoto H, Oizumi S, Hida T, Hotta K, Takiguchi Y. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. JTO Clin Res Rep 2020; 2: 100107. doi: 10.1016/j.jtocrr.2020.100107. PMID: 34589972.
  • 2019
    1. Suzuki A, Kondoh Y, Swigris JJ, Matsuda T, Kimura T, Kataoka K, Ando M, Hashimoto N, Sakamoto K, Hasegawa Y. Performance of the COPD Assessment Test in patients with connective tissue disease-associated interstitial lung disease. Respir Med, 2019;150:15-20
    2. Falcone M, Russo A, Shindo Y, Farcomeni A, Pieralli F, Cangemi R, Liu J, Xia J, Okumura J, Sano M, Jones C, Vannucchi V, Mancone M, Micek S, Xu F, Violi F, Kollef MA Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia. Antimicrob Agents Chemother, 2019;63(2): e01556-18
    3. Isobe Y, Ito S, Matsuda T, Iwano S, Uchida A, Takahashi N, Kojima T, Wakahara K, Yamaguchi E, Hasegawa Y. Longitudinal changes in pulmonary function and respiratory impedance of rheumatoid arthritis. Respir Physiol Neurobiol, 2019;261:1-8
    4. Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y. Prognostic impact and risk factors of immune-related pneumonitis in patients with non-small cell lung cancer who received programmed death-1 inhibitors. Clinical Lung Cancer, 2019; 20(6): 442-450
    5. Ando A, Hashimoto N, Sakamoto K, Omote N, Miyazaki S, Nakahara Y, Imaizumi K, Kawabe T, Hasegawa Y. Repressive role of stabilized hypoxia inducible factor 1α expression on transforming growth factor β-induced extracellular matrix production in lung cancer cells. Cancer Sci. 110(6):1959-1973, 2019. doi: 10.1111/cas.14027.
    6. Sugawara S, Inui N, Kanehara M, Morise M, Yoshimori K, Kumagai T, Fukui T, Minato K, Iwashima A, Takeda Y, Kubota K, Saeki T, Tamura T. Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Cancer, 2019; 125(22): 4076-83
    7. Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, Kozuki T, Miura S, Sasaki T, Tamiya A, Teraoka S, Tsubata Y, Yoshioka H, Hattori Y, Imamura CK, Katsuya Y, Matsui R, Minegishi Y, Mizugaki H, Nosaki K, Okuma Y, Sakamoto S, Sone T, Tanaka K, Umemura S, Yamanaka T, Amano S, Hasegawa K, Morita S, Nakajima K, Maemondo M, Seto T, Yamamoto N. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol. 2019; 24(7): 731-77
    8. Ito T, Nakamura A, Tanaka I, Tsuboi Y, Morikawa T, Nakajima J, Takai D, Fukayama M, Sekido Y, Niki T, Matsubara D, Murakami Y. CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis. Cancer Sci.20197;110(7):2284-2295
    9. Okumura J, Nakahara Y, Nakaguro M, shido Y, Hase T, Wakahara K, Hasimoto N, Hasegawa Y. BK virus-associated viruria and viremia in a patient with lymphangioleiomyomatosis after lung re-transplantation: A case report and review of the literature on BK virus infection post-lung transplantation. J Infect Chemother.2019;25(10):820-824
    10. Nishio T, Wakahara K, Suzuki Y, Nishio N, Majima S, Nakamura S, Teranishi M, Nakatochi M, Sone M, Hasegawa Y. Mixed cell type in airway inflammation is the dominant phenotype in asthma patients with severe chronic rhinosinusitis. Allergol Int. 2019; 68(4):515-520
  • 2018
    1. Suzuki A, Kimura T, Kataoka K, Matsuda T, Yokoyama T, Mori Y, Kondoh Y. Acute exacerbation of idiopathic pulmonary fibrosis triggered by Aspergillus empyema. Respiratory medicine case reports. 2018 ;23:103-106. doi: 10.1016/j.rmcr.2018.01.004
    2. Okuyama S, Nagaya T, Sato K, Ogata F, Maruoka Y, Choyke PL, Kobayashi H. Interstitial near-infrared photoimmunotherapy: effective treatment areas and light doses needed for use with fiber optic diffusers. Oncotarget. 2018 ;9(13):11159-11169. doi: 10.18632/oncotarget.24329
    3. Hashimoto N, Ando A, Iwano S, Sakamoto K, Okachi S, Matsuzaki A, Okada Y, Wakai K, Yokoi K, Hasegawa Y. Thin-section computed tomography-determined usual interstitial pneumonia pattern affects the decision-making process for resection in newly diagnosed lung cancer patients: a retrospective study. BMC pulmonary medicine. 2018 ;18(1):2. doi: 10.1186/s12890-017-0565-5
    4. Okachi S, Imaizumi K, Imai N, Shimizu T, Hase T, Morise M, Hashimoto N, Sato M, Hasegawa Y. Safety and efficacy of diagnostic flexible bronchoscopy in very old patients with lung cancer. European Geriatric Medicine. 2018 ;9(2):255–262. doi: 10.1007/s41999-018-0033-7
    5. Furukawa T, Kondoh Y, Taniguchi H, Yagi M, Matsuda T, Kimura T, Kataoka K, Johkoh T, Ando M, Hashimoto N, Sakamoto K, Hasegawa Y. A scoring system to predict the elevation of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis. The European respiratory journal. 2018 ;51(1):. doi: 10.1183/13993003.01311-2017
    6. Kondoh Y, Taniguchi H, Kataoka K, Furukawa T, Shintani A, Fujisawa T, Suda T, Arita M, Baba T, Ichikado K, Inoue Y, Kishi K, Kishaba T, Nishiyama O, Ogura T. Clinical spectrum and prognostic factors of possible UIP pattern on high-resolution CT in patients who underwent surgical lung biopsy. PLoS one. 2018 ;13(3):e0193608. doi: 10.1371/journal.pone.0193608
    7. Suzuki A, Kondoh Y, Swigris JJ, Ando M, Kimura T, Kataoka K, Yamano Y, Furukawa T, Numata M, Sakamoto K, Hasegawa Y. Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease. Respirology. (Carlton, Vic.) 2018 ; doi: 10.1111/resp.13293
    8. Shintani Y, Hasegawa S, Takuwa T, Aoe K, Kato K, Fujimoto N, Hida Y, Morise M, Moriya Y, Morohoshi T, Okumura M, Yoshino I. Prospective registry database of patients with malignant mesothelioma: directions for a future Japanese registry-based lung cancer study. Journal of thoracic disease. 2018 ;10(3):1968-1971. doi: 10.21037/jtd.2018.03.53
    9. Miyazawa A, Ito S, Asano S, Tanaka I, Sato M, Kondo M, Hasegawa Y. Regulation of PD-L1 expression by matrix stiffness in lung cancer cells. Biochemical and biophysical research communications. 2018 ;495(3):2344-2349. doi: 10.1016/j.bbrc.2017.12.115
    10. Tanaka I, Kawada K, Morise M, Hase T, Hayashi H, Sokai A, Fukatsu A, Kondo M, Nomura F, Hasegawa Y. A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting. Cancer Chemother Pharmacol. 2018 ;81(2):339-345. doi: 10.1007/s00280-017-3497-0.
    11. Okumura J, Shindo Y, Takahashi K, Sano M, Sugino Y, Yagi T, Taniguchi H, Saka H, Matsui S, Hasegawa Y; Central Japan Lung Study Group. Mortality in patients with community‐onset pneumonia at low risk of drug‐resistant pathogens: Impact of β‐lactam plus macrolide combination therapy. Respirology. 2018 ;23(5):526-534. doi: 10.1111/resp.13232
    12. Tang Q, Nagaya T, Liu Y, Horng H, Lin J, Sato K, Kobayashi H, Chen Y. 3D mesoscopic fluorescence tomography for imaging micro-distribution of antibody-photon absorber conjugates during near infrared photoimmunotherapy in vivo. J Control Release. 2018 ;279:171-180. doi: 10.1016/j.jconrel.2018.04.027.
    13. Nakajima K, Kimura T, Takakura H, Yoshikawa Y, Kameda A, Shindo T, Sato K, Kobayashi H, Ogawa M. Implantable wireless powered light emitting diode (LED) for near-infrared photoimmunotherapy: device development and experimental assessment in vitro and in vivo. Oncotarget. 2018 ;28(9):20048-20057. doi: 10.18632/oncotarget.25068.
    14. Tanaka I, Sato M, Kato T, Goto D, Kakumu T, Miyazawa A, Yogo N, Hase T, Morise M, Sekido Y, Girard L, Minna JD, Byers LA, Heymach JV, Coombes KR, Kondo M, Hasegawa Y. eIF2β, a subunit of translation-initiation factor EIF2, is a potential therapeutic target for non-small cell lung cancer. Cancer Sci. 2018 ;109(6):1843-1852. doi: 10.1111/cas.13602.
    15. Ohkubo H, Taniguchi H, Kondoh Y, Yagi M, Furukawa T, Johkoh T, Arakawa H, Fukuoka J, Niimi A. A Volumetric Computed Tomography Analysis of the Normal Lung in Idiopathic Pulmonary Fibrosis: The Relationship with the Survival. Intern Med. 2018 ;57(7):929-937. doi: 10.2169/internalmedicine.9508-17
    16. Sato M, Okachi S, Fukihara J, Shimoyama Y, Wakahara K, Sakakibara T, Hase T, Onishi Y, Ogura Y, Maeda O, Hasegawa Y. Lung Metastases from Bile Duct Adenocarcinoma Mimicking Chronic Airway Infection and Causing Diagnostic Difficulty. Intern Med. 2018 ;57(10):1429-1432. doi: 10.2169/internalmedicine.9718-17
    17. Majima S, Okachi S, Asano M, Wakahara K, Hashimoto M, Sato M, Ishigami M, Hasegawa Y. Pseudomembranous Invasive Tracheobronchial Aspergillosis with Fulminant Hepatitis and Hemophagocytic Syndrome. Internal Med. 2018 ;57(16):2371-2375. doi: 10.2169/internalmedicine.9673-17
    18. Tanaka I, Morise M, Kodama Y, Matsui A, Ozawa N, Ozone S, Goto D, Miyazawa A, Hase T, Hashimoto N, Sato M, Hasegawa Y. Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations. Lung Cancer. 2018 ;doi: 10.1016/j.lungcan.2018.11.018
    19. Sato K, Ando K, Okuyama S, Moriguchi S, Ogura T, Totoki S, Hanaoka H, Nagaya T, Kokawa R, Takakura H, Nishimura M, Hasegawa Y, Choyke PL, Ogawa M, Kobayashi H. Photo-induced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies; A mechanism of cancer cell cytotoxicity after near infrared photoimmunotherapy. ACS Cent. Sci. 2018 ;4(11):pp 1559–1569. doi: 10.1021/acscentsci.8b00565.
    20. Kobayashi D, Shindo Y, Ito R, Iwaki M, Okumura J, Sakakibara T, Yamaguchi I, Yagi T, Ogasawara T, Sugino Y, Taniguchi H, Saito H, Saka H, Kawamura T, Hasegawa Y. Validation of the prediction rules identifying drug-resistant pathogens in community-onset pneumonia. Infect Drug Resist. 2018 ;11:1703-1713. doi: 10.2147/IDR.S165669
    21. Sato M, Matsui A, Shimoyama Y, Omote N, Morise M, Hase T, Tanaka I, Suzuki K, Hasegawa Y.. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib. Intern Med. 2018 ;57(23):3429-3432. doi: 10.2169/internalmedicine.0999-18.
    22. Asano S, Ito S, Morosawa M, Furuya K, Naruse K, Sokabe M, Yamaguchi E, Hasegawa Y. Cyclic stretch enhances reorientation and differentiation of 3-D culture model of human airway smooth muscle. Biochemistry and Biophysics Reports. 2018 ;16:32-38. doi: 10.1016/j.bbrep.2018.09.003
    23. Teramachi R, Kondoh Y, Kataoka K, Taniguchi H, Matsuda T, Kimura T, Yokoyama T, Yamano Y, Furukawa T, Sakamoto K, Hashimoto N, Hasegawa Y. Outcomes with newly proposed classification of acute respiratory deterioration in idiopathic pulmonary fibrosis. Respir Med. 2018 ;143():147-152. doi: 10.1016/j.rmed.2018.09.011
    24. Yamano Y, Taniguchi H, Kondoh Y, Ando M, Kataoka K, Furukawa T, Johkoh T, Fukuoka J, Sakamoto K, Hasegawa Y. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: Two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respirology. 2018 ;23(11):1041-1048. doi: 10.1111/resp.13365
    25. Maruoka Y, Nagaya T, Sato K, Ogata F, Okuyama S, Choyke PL, Kobayashi H. Near Infrared Photoimmunotherapy with Combined Exposure of External and Interstitial Light Sources. Mol Pharm. 2018 ;15(9):3634-3641.

Research Keywords

Lung cancer; malignant mesothelioma; interstitial pneumonia; pulmonary fibrosis; chronic obstructive pulmonary disease (COPD); asthma; pneumonia; pulmonary infections; respiratory failure; gene therapy; molecular target therapy; immunotherapy.